erythromycin 20 MG/ML Topical Solution

What the CMS Formulary Data Shows for erythromycin 20 MG/ML Topical Solution

Per the CMS 2026 Part D formulary file, erythromycin 20 MG/ML Topical Solution (RxNorm concept RXCUI 318202, generic name erythromycin) appears on 324 distinct formulary files spanning 5,045 Medicare Part D plan offerings - 99.6% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.1.

Real-world access to erythromycin 20 MG/ML Topical Solution depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 39.8% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,861 Part D beneficiaries filled erythromycin 20 MG/ML Topical Solution in 2023, with total plan-and-beneficiary spending of $4,499,767 and an average per-beneficiary annual cost of $2,417.93. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry erythromycin 20 MG/ML Topical Solution today.